IRSF funds male inclusion in Rett syndrome trial
The International Rett Syndrome Foundation has funded a protocol change that could let males join Unravel Biosciences’ REVOLUTION Phase 1 trial in Colombia. If approved by Colombian regulators in January 2027, the study would become only the second Rett syndrome trial worldwide to enroll males.
Why it matters: - The amendment could open investigational Rett syndrome research to males, a group historically left out of clinical trials. - If approved, REVOLUTION would become only the second Rett syndrome trial worldwide to enroll males. - The change could generate evidence to support more inclusive trial designs in future Rett syndrome studies. - The funding is the first investment from IRSF’s Males with Rett Fund, signaling a targeted push to change research access for boys and men with Rett syndrome.
What happened: - The International Rett Syndrome Foundation funded a protocol amendment for Unravel Biosciences’ ongoing REVOLUTION Phase 1 clinical trial in Colombia. - The amendment would allow males to participate in the trial, which is evaluating an investigational oral treatment for Rett syndrome. - IRSF said the investment is the first project supported through its MR. Males with Rett Fund. - The amended protocol has already been approved by the Clinical Research Ethics Committee of Antioquia, known as CEICA. - Separate approval from Colombia’s health regulator, INVIMA, is expected in January 2027.
The details: - REVOLUTION is evaluating RVL-001, an investigational oral formulation of vorinostat identified through Unravel Biosciences’ drug discovery platform as a potential Rett syndrome treatment. - Preclinical research published in July 2025 showed improvements in neurological, gastrointestinal and other symptoms in animal models of Rett syndrome. - The Phase 1 study began dosing participants in May 2026 at the PECET clinical research center in Medellín, Colombia. - The study is designed to enroll 15 participants ages 6 to 21. - The placebo-controlled trial is measuring safety, tolerability and preliminary treatment effects of RVL-001. - The amended protocol would expand the age range to 3 to 25. - The protocol change would allow males to enroll within the existing participant target. - Researchers would also be able to test whether the same clinical trial endpoints used for females can measure treatment responses in males. - The trial includes RNA sequencing to track gene expression in each participant. - That molecular data could help researchers better understand individual treatment responses and identify who may benefit most from specific therapies. - IRSF launched the $1 million MR. Males with Rett Fund in August 2026. - The fund was created to address barriers that have kept boys and men with Rett syndrome from timely diagnosis, care, trial participation and access to potential treatments. - Rett syndrome was long considered a disorder affecting girls, which left many males overlooked in diagnosis, care and research. - IRSF says the fund is guided by an advisory board that includes families of males with Rett syndrome. - The fund supports projects that are scientifically sound and explicitly include males with Rett syndrome. - Additional information about the trial is available at the clinical trial listing. - More information about the fund is available at IRSF’s MR. Males with Rett Fund page.
Between the lines: - The amendment is about more than enrollment numbers. It also tests whether existing Rett syndrome measures work well for males, which has been a gap in the field. - The RNA sequencing component suggests the study is aiming to connect clinical outcomes with biological markers, not just symptom change. - IRSF is using a funding vehicle to force a practical change in how Rett syndrome research is designed, rather than waiting for broader consensus. - Unravel Biosciences is positioning the trial as part of a broader individualized medicine strategy that combines clinical data with molecular readouts.
What's next: - Colombia’s INVIMA is expected to rule on the protocol amendment in January 2027. - If approved, the trial could begin enrolling males under the revised protocol. - Researchers will then assess safety, tolerability, preliminary efficacy and whether the trial’s endpoints capture treatment response across sexes. - IRSF said the MR. Fund will support additional projects, with more investments to follow.
The bottom line: - IRSF is trying to turn male inclusion in Rett syndrome research from an exception into a standard practice, starting with one amended trial in Colombia.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
International Tech Times
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.